You Searched For: 8-Bromoadenosine+3\',5\'-cyclic+Monophosphothioate,+Rp-Isomer+sod

Supplier: ENZO LIFE SCIENCES AG

Description: Inhibitor of cAMP-dependent protein kinase (PKA), preferentially binding to type I PKA. Lipophilic analog of Rp-cAMPS. Resistant to mammalian cyclic nucleotide-dependent phosphodiesterases. Significantly more lipophilic and membrane permeant as compared to Rp-cAMPS or 8-Br-cAMP.

New Product

Catalog Number: (ENZOALX480025M001)

Supplier: ENZO LIFE SCIENCES AG

Description: PKA activator.

UOM: 1 * 1 mg

New Product Sale

Catalog Number: (ENZOALX480085M001)

Supplier: ENZO LIFE SCIENCES AG

Description: Competitive inhibitor of cyclic AMP-dependent protein kinase I and II.Metabolic stability towards mammalian cyclic nucleotide- responsive phosphodiesterases.
Discriminates between protein kinase A (antagonist) and some other cyclic AMP receptors, e.g. channels or CAP 3 (agonist).Membrane-permeant for several systems (for improved permeability more lipophilic analogues e.g. Rp-8-Br-cAMPS are recommended).

UOM: 1 * 1 mg

New Product Sale

Catalog Number: (ENZOALX480072M001)

Supplier: ENZO LIFE SCIENCES AG

Description: Inhibitor of cGMP-dependent protein kinase (PKG) 1α (cGMP antagonist). Resistant against mammalian cyclic nucleotid-dependent phosphodiesterases. No metabolic side effects. Low membrane permeability.

UOM: 1 * 1 mg

New Product Sale

Catalog Number: (ENZOBMLCN2060001)

Supplier: ENZO LIFE SCIENCES AG

Description: A cell-permeable cGMP antagonist which is resistant to hydrolysis by cyclic nucleotide phosphodiesterases (Ki=0.5 µM). No metabolic side effects. Significantly more lipophilic and membrane permeant as compared to Rp-cGMPS or Rp-8-Br-cGMPS

UOM: 1 * 1 mg

New Product Sale

Supplier: ENZO LIFE SCIENCES AG

Description: Potent selective inhibitor of cGMP-dependent protein kinase 1α, 1β and type II. Resistant to mammalian cyclic nucleotide-dependent phosphodiesterases, no metabolic side effects. Significantly more lipophilic and membrane permeant as compared to Rp-cGMPS or Rp-8-Br-cGMPS.

New Product

Supplier: ENZO LIFE SCIENCES AG

Description: PKA activator.

New Product

Supplier: Apollo Scientific

Description: 4-Methyl-1,3,2-dioxathiolane-2-oxide (mixture of isomers) 98%

Catalog Number: (ENZOBMLCN1350001)

Supplier: ENZO LIFE SCIENCES AG

Description: Rp-cAMPS is a potent and specific competitive inhibitor of the activation of cAMP-dependent protein kinases by cAMP (IC50=4.9 µM) . Its cell permeability and complete resistance to cyclic nucleotide phosphodiesterases make it a unique tool for studying cAMP-dependent signaling. Significantly more lipophilc as compared to cAMP and thus membrane permeable in many biological systems. This product is not sterile.

UOM: 1 * 1 mg

New Product Sale

Catalog Number: (ENZOBMLCN2160500)

Supplier: ENZO LIFE SCIENCES AG

Description: Cell-permeable, phosphodiesterase-resistant cGMP antagonist. Reversed NO stimulation of random migration in rabbit neutrophils. Used at 30µM to cometively inhibit 8-Br-cGMP relaxation of rabbit aortas. The product is not sterile. Resistant to nucleotide-dependent phosphodiesterases; no metabolic side effects. Significantly more lipophilic and membrane permeant as compared to cyclic GMP or Rp-cGMPS.

UOM: 1 * 500 µG

New Product Sale

Supplier: Merck

Description: Purospher® STAR RP-8 endcapped, like Purospher® STAR RP-18 endcapped, is based on high purity silica and has an almost complete surface coverage. Thus, Purospher® STAR RP-8 provides excellent peak symmetry for acidic, basic and even chelating compounds, highest column efficiency in terms of the number of theoretical plates, and exceptional stability from pH 1,5 to 10,5. In addition, they are ideal for a wide range of applications. As the sorbent is less hydrophobic than Purospher® STAR RP-18 endcapped, analytes will typically elute faster on the C8 phase. Purospher® STAR RP-8 endcapped provides enhanced selectivity for positional isomers and symmetrical peak shapes for strongly basic and less hydrophobic compounds.

MSDS

Catalog Number: (BOSSBS-11332R-A350)

Supplier: Bioss

Description: Glutamic acid rich protein (GARP) is a soluble protein localized to the outer segments of the rod photoreceptor. It forms a subunit of cyclic nucleotide-gated (CNG) channels, nonselective cation channels, which play important roles in both visual and olfactory signal transduction. When associated with CNGA1, it is involved in the regulation of ion flow into the rod photoreceptor outer segment (ROS), in response to light-induced alteration of the levels of intracellular cGMP. There are 3 isoforms produced by alternative splicing. Isoform GARP2 is a high affinity rod photoreceptor phosphodiesterase (PDE6)-binding protein that modulates its catalytic properties; it is a regulator of spontaneous activation of rod PDE6, thereby serving to lower rod photoreceptor 'dark noise' and allowing these sensory cells to operate at the single photon detection limit. Defects in GARP are the cause of retinitis pigmentosa type 25 (RP25). RP leads to degeneration of retinal photoreceptor cells. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

UOM: 1 * 100 µl

Sale

Catalog Number: (BOSSBS-11332R)

Supplier: Bioss

Description: Glutamic acid rich protein (GARP) is a soluble protein localized to the outer segments of the rod photoreceptor. It forms a subunit of cyclic nucleotide-gated (CNG) channels, nonselective cation channels, which play important roles in both visual and olfactory signal transduction. When associated with CNGA1, it is involved in the regulation of ion flow into the rod photoreceptor outer segment (ROS), in response to light-induced alteration of the levels of intracellular cGMP. There are 3 isoforms produced by alternative splicing. Isoform GARP2 is a high affinity rod photoreceptor phosphodiesterase (PDE6)-binding protein that modulates its catalytic properties; it is a regulator of spontaneous activation of rod PDE6, thereby serving to lower rod photoreceptor 'dark noise' and allowing these sensory cells to operate at the single photon detection limit. Defects in GARP are the cause of retinitis pigmentosa type 25 (RP25). RP leads to degeneration of retinal photoreceptor cells. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

UOM: 1 * 100 µl

Sale

Catalog Number: (BOSSBS-11332R-A488)

Supplier: Bioss

Description: Glutamic acid rich protein (GARP) is a soluble protein localized to the outer segments of the rod photoreceptor. It forms a subunit of cyclic nucleotide-gated (CNG) channels, nonselective cation channels, which play important roles in both visual and olfactory signal transduction. When associated with CNGA1, it is involved in the regulation of ion flow into the rod photoreceptor outer segment (ROS), in response to light-induced alteration of the levels of intracellular cGMP. There are 3 isoforms produced by alternative splicing. Isoform GARP2 is a high affinity rod photoreceptor phosphodiesterase (PDE6)-binding protein that modulates its catalytic properties; it is a regulator of spontaneous activation of rod PDE6, thereby serving to lower rod photoreceptor 'dark noise' and allowing these sensory cells to operate at the single photon detection limit. Defects in GARP are the cause of retinitis pigmentosa type 25 (RP25). RP leads to degeneration of retinal photoreceptor cells. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

UOM: 1 * 100 µl

Sale

Catalog Number: (BOSSBS-11332R-CY5)

Supplier: Bioss

Description: Glutamic acid rich protein (GARP) is a soluble protein localized to the outer segments of the rod photoreceptor. It forms a subunit of cyclic nucleotide-gated (CNG) channels, nonselective cation channels, which play important roles in both visual and olfactory signal transduction. When associated with CNGA1, it is involved in the regulation of ion flow into the rod photoreceptor outer segment (ROS), in response to light-induced alteration of the levels of intracellular cGMP. There are 3 isoforms produced by alternative splicing. Isoform GARP2 is a high affinity rod photoreceptor phosphodiesterase (PDE6)-binding protein that modulates its catalytic properties; it is a regulator of spontaneous activation of rod PDE6, thereby serving to lower rod photoreceptor 'dark noise' and allowing these sensory cells to operate at the single photon detection limit. Defects in GARP are the cause of retinitis pigmentosa type 25 (RP25). RP leads to degeneration of retinal photoreceptor cells. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

UOM: 1 * 100 µl

Sale

Catalog Number: (BOSSBS-11332R-CY7)

Supplier: Bioss

Description: Glutamic acid rich protein (GARP) is a soluble protein localized to the outer segments of the rod photoreceptor. It forms a subunit of cyclic nucleotide-gated (CNG) channels, nonselective cation channels, which play important roles in both visual and olfactory signal transduction. When associated with CNGA1, it is involved in the regulation of ion flow into the rod photoreceptor outer segment (ROS), in response to light-induced alteration of the levels of intracellular cGMP. There are 3 isoforms produced by alternative splicing. Isoform GARP2 is a high affinity rod photoreceptor phosphodiesterase (PDE6)-binding protein that modulates its catalytic properties; it is a regulator of spontaneous activation of rod PDE6, thereby serving to lower rod photoreceptor 'dark noise' and allowing these sensory cells to operate at the single photon detection limit. Defects in GARP are the cause of retinitis pigmentosa type 25 (RP25). RP leads to degeneration of retinal photoreceptor cells. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

UOM: 1 * 100 µl

Sale